In Vitro Assessment of Cardiac Risk in Drug Discovery

Clear decision-making data for your project team is vital to ensure you avoid costly issues related to QTc and QRS cardiac liabilities in the clinic. Hear from industry experts, Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company) and Steve Jenkinson (Metrion).
Recommended Publications
Latest Publications
Studying ion channels on the lysosomal membrane

In this video we demonstrate how to perform the lysosomal patch clamp technique to study ion channels on the lysosomal membrane.

Breaking New Ground in Chronic Pain Relief: Advancements in Drug Discovery for Trigeminal Neuralgia

This webinar presents data on sensory neuron ion channels, sensory neuron excitability and mechanism underlying trigeminal neuralgia.

View All
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram